Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies - 21/11/24
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Background |
In an exploratory 91-participant phase 2a clinical trial (AscenD-LB, NCT04001517) in dementia with Lewy bodies (DLB), neflamapimod showed improvement over placebo on multiple clinical endpoints. To confirm those results, a phase 2b clinical study (RewinD-LB, NCT05869669 ) that is similar to AscenD-LB has been initiated.
Objectives |
To optimize the choice of patient population, primary endpoint, and biomarker evaluations in RewinD-LB.
Design |
Evaluation of the efficacy results from AscenD-LB, the main results of which, and a re-analysis after stratification for absence or presence of AD co-pathology (assessed by plasma ptau181), have been published. In addition, the MRI data from a prior phase 2a clinical trial in Early Alzheimer’s disease (AD), were reviewed.
Setting |
22 clinical sites in the US and 2 in the Netherlands.
Participants |
Probable DLB by consensus criteria and abnormal dopamine uptake by DaTscan™ (Ioflupane I123 SPECT).
Intervention |
Neflamapimod 40mg capsules or matching placebo capsules, twice-a-day (BID) or three-times-a-day (TID), for 16 weeks.
Measurements |
6-test Neuropsychological Test Battery (NTB) assessing attention and executive function, Clinical Dementia Rating Sum-of-Boxes (CDR-SB), Timed Up and Go (TUG), International Shopping List Test (ISLT).
Results |
Within AscenD-LB, patients without evidence of AD co-pathology exhibited a neflamapimod treatment effect that was greater than that in the overall population and substantial (cohen’s d effect size vs. placebo ≥ for CDR-SB, TUG, Attention and ISLT-recognition). In addition, the CDR-SB and TUG performed better than the cognitive tests to demonstrate neflamapimod treatment effect in comparison to placebo. Further, clinical trial simulations indicate with 160-patients (randomized 1:1), RewinD-LB conducted in patients without AD co-pathology has >95% (approaching 100%) statistical power to detect significant improvement over placebo on the CDR-SB. Preliminary evidence of positive treatment effects on beta functional connectivity by EEG and basal forebrain atrophy by MRI were obtained in AscenD-LB and the Early AD study, respectively.
Conclusion |
In addition to use of a single dose regimen of neflamapimod (40mg TID), key distinctions between phase 2b and phase 2a include RewinD-LB (1) excluding patients with AD co-pathology, (2) having CDR-SB as the primary endpoint, and (3) having MRI studies to evaluate effects on basal forebrain atrophy.
El texto completo de este artículo está disponible en PDF.Key words : Neflamapimod, dementia with Lewy bodies (DLB), clinical trial, p38 MAPK
Esquema
Vol 11 - N° 3
P. 549-557 - mai 2024 Regresar al número
Artículo precedente
- At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer’s Disease: Feasibility, Safety and Pharmacodynamic Impact
- Frank G. Boess, M.A. Scelsi, T. Grimmer, R.J. Perry, M. Tonietto, G. Klein, C. Hofmann, M. Salami, J. Wojtowicz, C.J. Lansdall, C. Lane, G.A. Kerchner, J. Smith, R.S. Doody, GRADUATION Investigators and the gantenerumab study group
- Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials
- Haiyan Liu, J. Li, E. Ziegemeier, S. Adams, E. McDade, D.B. Clifford, Y. Cao, G. Wang, Y. Li, S.L. Mills, A.M. Santacruz, S. Belyew, J.D. Grill, B.J. Snider, C.J. Mummery, G. Surti, D. Hannequin, D. Wallon, S.B. Berman, I.Z. Jimenez-Velazquez, E.D. Roberson, C.H. van Dyck, L.S. Honig, R. Sanchez-Valle, W.S. Brooks, S. Gauthier, D. Galasko, C.L. Masters, J. Brosch, G.-Y.R. Hsiung, S. Jayadev, M. Formaglio, M. Masellis, R. Clarnette, J. Pariente, B. Dubois, F. Pasquier, R.J. Bateman, Jorge J. Llibre-Guerra, DIAN-TU Study Team
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.